The Birmingham-based clinical reference lab announced Thursday that its new tests will measure sensitivity to Warfarin and Plavix – two widely prescribed blood thinning drugs – and perform the thrombophilia risk test. The thrombophilia test looks for specific gene mutations in patients who have the blood clotting disorder.
The Warfarin and Plavix tests will see how patients metabolize those drugs. An Atherotech news release said those tests can help doctors determine the right dosage or consider a medication change to help prevent clots that can lead to heart attack or stroke.
The full article is located at Birmingham Business Journal